Ionis Pharmaceuticals, Inc. Overview
Pro stress-test →Ionis is unlocking the rapidly expanding potential of RNA- and DNA-targeted medicines to enable better futures for people living with serious diseases. The company has evolved from a research pioneer to a commercial-stage biopharmaceutical company, recently achieving independent product launches after decades of relying on partners. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need.
Strategic Profile
Pro stress-test →Ionis reduced its reliance on partners and started commercializing its own pharmaceuticals, forming its own sales and regulatory teams and launching more pharmaceuticals independently. The company is poised for two additional independent launches of breakthrough therapies – olezarsen for severe hypertriglyceridemia, Ionis' first launch in a large patient population, and zilganersen for Alexander disease, Ionis' first independent launch.
Competitive Landscape
Pro stress-test →As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. The company competes with other specialized biotech firms in rare genetic and neurological diseases. Main competitors include companies with RNA-targeting capabilities like Alnylam Pharmaceuticals, Wave Life Sciences, and broader biopharma players like Biogen (partner on Spinraza).
Industry Context
Ionis Pharmaceuticals, Inc. operates in Biopharmaceutical - RNA-Targeted Medicines & Gene Therapy.
Key facts
Founded: 1989 · Headquarters: Carlsbad, US